• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

特发性肺纤维化的药物发现与开发：挑战与机遇

Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.

作者信息

Cruwys Simon, Hein Peter, Humphries Bob, Black Darcey

机构信息

TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.

TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.

出版信息

Drug Discov Today. 2020 Dec;25(12):2277-2283. doi: 10.1016/j.drudis.2020.09.019. Epub 2020 Sep 30.

DOI:10.1016/j.drudis.2020.09.019
PMID:33010480
Abstract

The pharmacological and adverse effect profiles of the two approved therapies for IPF make the development of new therapies challenging. Considering the similarity of the characteristics of drug candidates to Standard of Care is important in defining positioning and development strategies for this disease.

摘要

两种已获批的特发性肺纤维化（IPF）治疗方法的药理特性和不良反应情况使得开发新疗法具有挑战性。在确定该疾病的定位和开发策略时，考虑候选药物特性与标准治疗的相似性很重要。

相似文献

1
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.特发性肺纤维化的药物发现与开发：挑战与机遇
Drug Discov Today. 2020 Dec;25(12):2277-2283. doi: 10.1016/j.drudis.2020.09.019. Epub 2020 Sep 30.
2
Therapeutic targets and early stage clinical trials for pulmonary fibrosis.肺纤维化的治疗靶点和早期临床试验。
Expert Opin Investig Drugs. 2019 Jan;28(1):19-28. doi: 10.1080/13543784.2019.1554054. Epub 2018 Dec 6.
3
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.获批疗法时代特发性肺纤维化临床试验的设计
Am J Respir Crit Care Med. 2019 Jul 15;200(2):133-139. doi: 10.1164/rccm.201903-0592PP.
4
Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design.新型特发性肺纤维化治疗药物的研发：靶点选择和临床试验设计的进展。
Chest. 2015 Oct;148(4):1083-1092. doi: 10.1378/chest.14-3218.
5
Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective.从药物发现角度探索治疗特发性肺纤维化的新型分子靶点
Curr Med Chem. 2017;24(22):2439-2458. doi: 10.2174/0929867324666170526123607.
6
Current models of pulmonary fibrosis for future drug discovery efforts.用于未来药物研发工作的肺纤维化当前模型。
Expert Opin Drug Discov. 2020 Aug;15(8):931-941. doi: 10.1080/17460441.2020.1755252. Epub 2020 May 12.
7
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.治疗特发性肺纤维化：当前机遇与未来挑战
Clin Respir J. 2012 Jul;6(3):129-30. doi: 10.1111/j.1752-699X.2012.00303.x.
8
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis.开发特发性肺纤维化新化合物时的陷阱。
Curr Opin Pulm Med. 2017 Sep;23(5):426-431. doi: 10.1097/MCP.0000000000000407.
9
Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules.特发性肺纤维化的最新进展：发病机制、治疗策略和候选分子。
Future Med Chem. 2019 Oct;11(19):2595-2620. doi: 10.4155/fmc-2019-0111.
10
Therapeutic targets in idiopathic pulmonary fibrosis.特发性肺纤维化的治疗靶点。
Respir Med. 2017 Oct;131:49-57. doi: 10.1016/j.rmed.2017.07.062. Epub 2017 Aug 1.

引用本文的文献

1
[ alleviates bleomycin-induced pulmonary fibrosis in mice by inhibiting transformation of lung fibroblasts into myofibroblast].通过抑制肺成纤维细胞向肌成纤维细胞转化减轻博来霉素诱导的小鼠肺纤维化
Nan Fang Yi Ke Da Xue Xue Bao. 2025 Aug 20;45(8):1672-1681. doi: 10.12122/j.issn.1673-4254.2025.08.12.
2
Optimized administration of human embryonic stem cell-derived immunity-and-matrix regulatory cells for mouse lung injury and fibrosis.优化人胚胎干细胞来源的免疫和基质调节细胞在小鼠肺损伤和纤维化中的应用。
Stem Cell Res Ther. 2024 Oct 8;15(1):344. doi: 10.1186/s13287-024-03945-4.
3
VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis.
VISTA（PD-1H）是限制肺纤维化的关键免疫调节剂。
Am J Respir Cell Mol Biol. 2023 Jul;69(1):22-33. doi: 10.1165/rcmb.2022-0219OC.
4
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.博来霉素诱导的肺纤维化缓解后细胞内羟脯氨酸印迹。
Eur Respir J. 2022 May 5;59(5). doi: 10.1183/13993003.00864-2021. Print 2022 May.